These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10323777)

  • 21. Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency.
    Santos RD; Schaefer EJ; Asztalos BF; Polisecki E; Wang J; Hegele RA; Martinez LR; Miname MH; Rochitte CE; Da Luz PL; Maranhão RC
    J Lipid Res; 2008 Feb; 49(2):349-57. PubMed ID: 17991756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum.
    Fournier N; Atger V; Paul JL; Sturm M; Duverger N; Rothblat GH; Moatti N
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1283-92. PubMed ID: 10807744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production.
    Anthanont P; Polisecki E; Asztalos BF; Diffenderfer MR; Barrett PH; Millar JS; Billheimer J; Cuchel M; Rader DJ; Schaefer EJ
    Atherosclerosis; 2014 Aug; 235(2):470-6. PubMed ID: 24950002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ApoA-IHelsinki (Lys107-->0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency.
    Tilly-Kiesi M; Zhang Q; Ehnholm S; Kahri J; Lahdenperä S; Ehnholm C; Taskinen MR
    Arterioscler Thromb Vasc Biol; 1995 Sep; 15(9):1294-306. PubMed ID: 7670941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice.
    Tohyama J; Billheimer JT; Fuki IV; Rothblat GH; Rader DJ; Millar JS
    Atherosclerosis; 2009 Jun; 204(2):418-23. PubMed ID: 18990393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I(Milano).
    Chiesa G; Stoltzfus LJ; Michelagnoli S; Bielicki JK; Santi M; Forte TM; Sirtori CR; Franceschini G; Rubin EM
    Atherosclerosis; 1998 Jan; 136(1):139-46. PubMed ID: 9544740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene.
    Lackner KJ; Dieplinger H; Nowicka G; Schmitz G
    J Clin Invest; 1993 Nov; 92(5):2262-73. PubMed ID: 7693760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients.
    Kempen HJ; Asztalos BF; Moerland M; Jeyarajah E; Otvos J; Kallend DG; Bellibas SE; Wijngaard PL
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):736-42. PubMed ID: 26916733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice.
    Tiniakou I; Kanaki Z; Georgopoulos S; Chroni A; Van Eck M; Fotakis P; Zannis VI; Kardassis D
    Atherosclerosis; 2015 Nov; 243(1):77-85. PubMed ID: 26363436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant.
    Gomaraschi M; Baldassarre D; Amato M; Eligini S; Conca P; Sirtori CR; Franceschini G; Calabresi L
    Circulation; 2007 Nov; 116(19):2165-72. PubMed ID: 17967773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity.
    Salminen A; Åström P; Metso J; Soliymani R; Salo T; Jauhiainen M; Pussinen PJ; Sorsa T
    FASEB J; 2015 Apr; 29(4):1435-45. PubMed ID: 25550459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of dietary maritime pine (Pinus pinaster)-seed oil on high-density lipoprotein levels and in vitro cholesterol efflux in mice expressing human apolipoprotein A-I.
    Asset G; Leroy A; Bauge E; Wolff RL; Fruchart JC; Dallongeville J
    Br J Nutr; 2000 Sep; 84(3):353-60. PubMed ID: 10967614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of High-Density Lipoprotein Charge Heterogeneity, Cholesterol Efflux Capacity, and the Expression of High-Density Lipoprotein-Related Genes in Mononuclear Cells to the HDL-Cholesterol Level.
    Dergunov AD; Litvinov DY; Bazaeva EV; Dmitrieva VG; Nosova EV; Rozhkova AV; Dergunova LV
    Lipids; 2018 Oct; 53(10):979-991. PubMed ID: 30430582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study.
    Sirtori CR; Calabresi L; Franceschini G; Baldassarre D; Amato M; Johansson J; Salvetti M; Monteduro C; Zulli R; Muiesan ML; Agabiti-Rosei E
    Circulation; 2001 Apr; 103(15):1949-54. PubMed ID: 11306522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance of cationized LDL cholesterol from a muscle depot is not enhanced in human apolipoprotein A-IV transgenic mice.
    Stein Y; Stein O; Duverger N; Halperin G; Dabach Y; Hollander G; Ben-Naim M
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):179-84. PubMed ID: 10634815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice.
    Hosoai H; Webb NR; Glick JM; Tietge UJ; Purdom MS; de Beer FC; Rader DJ
    J Lipid Res; 1999 Apr; 40(4):648-53. PubMed ID: 10191288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterozygosity for apolipoprotein A-I(R160L)Oslo is associated with low levels of high density lipoprotein cholesterol and HDL-subclass LpA-I/A-II but normal levels of HDL-subclass LpA-I.
    Leren TP; Bakken KS; Daum U; Ose L; Berg K; Assmann G; von Eckardstein A
    J Lipid Res; 1997 Jan; 38(1):121-31. PubMed ID: 9034206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Compendium of the Biological Effects of Apolipoprotein A-I
    Parolini C
    J Pharmacol Exp Ther; 2020 Jan; 372(1):54-62. PubMed ID: 31649050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ApoA-I mutations, L202P and K131del, in HDL from heterozygotes with low HDL-C.
    Ljunggren S; Levels JH; Turkina MV; Sundberg S; Bochem AE; Hovingh K; Holleboom AG; Lindahl M; Kuivenhoven JA; Karlsson H
    Proteomics Clin Appl; 2014 Apr; 8(3-4):241-50. PubMed ID: 24273187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.